Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.
- DOI
- 10.1186/s12933-022-01607-4
- Published
- 2022 Sep 3
- Container
- Cardiovascular diabetology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s12933-022-01607-4,
title = {Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.},
author = {Leccisotti L and Cinti F and Sorice GP and D'Amario D and Lorusso M and Guzzardi MA and Mezza T and Gugliandolo S and Cocchi C and Capece U and Indovina L and Ferraro PM and Iozzo P and Crea F and Giordano A and Giaccari A},
year = {2022},
journal = {Cardiovascular diabetology},
doi = {10.1186/s12933-022-01607-4},
url = {https://doi.org/10.1186/s12933-022-01607-4}
}RIS
TY - JOUR TI - Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report. AU - Leccisotti L AU - Cinti F AU - Sorice GP AU - D'Amario D AU - Lorusso M AU - Guzzardi MA AU - Mezza T AU - Gugliandolo S AU - Cocchi C AU - Capece U AU - Indovina L AU - Ferraro PM AU - Iozzo P AU - Crea F AU - Giordano A AU - Giaccari A PY - 2022 JO - Cardiovascular diabetology DO - 10.1186/s12933-022-01607-4 UR - https://doi.org/10.1186/s12933-022-01607-4 ER -
APA
L, L., F, C., GP, S., D, D., M, L., MA, G., T, M., S, G., C, C., U, C., L, I., PM, F., P, I., F, C., A, G., & A, G. (2022). Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report.. Cardiovascular diabetology. https://doi.org/10.1186/s12933-022-01607-4
Source records
- pubmed · retrieved 2026-09-26T18:50:00.615Z